Skip to main content
2023 ACVIM Forum Main banner
Final Program


2023 Event Program
Icon Legend
This session is not on your agenda.
This session is on your agenda. Click again to remove it.
Presentation Icons
ACVIM Resident Research Award Eligible
ACVIM Resident Research Award Eligible
Additional Fees May Be Required
Additional Fees May Be Required
By Invite Only
By Invite Only
Capturing for On Demand
Capturing for On Demand
Cardiology Research Abstract Award Eligible
Cardiology Research Abstract Award Eligible
ERC Approved Lecture for ACVIM Residency
ERC Approved Lecture for ACVIM Residency
ePoster
ePoster
Livestream
Livestream
One Health
One Health
Pre-Registration Required
Pre-Registration Required
RACE-Approved
RACE-Approved
Research Abstract
Research Abstract
Specialty Symposium
Specialty Symposium
State-of-the-Art (SOTA) Presentation
State-of-the-Art (SOTA) Presentation
Veterinary Technician
Veterinary Technician
Back

Michael S. Pepper, MBChB (Cape Town), PhD (Geneva), MD (Geneva), Privat Docent (Geneva)

Director, Institute for Cellular and Molecular Medicine
University of Pretoria
Pretoria, Gauteng, South Africa

Michael Pepper is Director of the Institute for Cellular and Molecular Medicine, Director of the South African Medical Research Council Extramural Unit for Stem Cell Research and Therapy, and Research Professor in the Department of Immunology in the Faculty of Health Sciences at the University of Pretoria. He is also professeur associé in the Department of Genetic Medicine and Development in the Faculty of Medicine at the University of Geneva, Switzerland.

Michael obtained his MBChB in 1982 from the Faculty of Medicine at the University of Cape Town, and moved to Geneva in 1986, where he obtained his PhD in 1990, MD in 1992 and Privat Docent in 1997. He returned to South Africa in July 2004. Michael maintains research and teaching commitments in Pretoria and Geneva.

Michael has worked extensively in the field of clinically-oriented (translational) molecular cell biology and has made seminal contributions to understanding the mechanisms of angiogenesis and lymphangiogenesis. His current scientific interests are in the fields of cell and gene therapy and genetic predisposition to disease, as well as the ethical, legal and social implications (ELSI) of work in these fields.

Presentation(s):